MaxCyte, Inc. Common Stock (MXCT)
MaxCyte, Inc. is a global biotechnology company specializing in the development and commercialization of advanced cell engineering and transfection technologies. Its platform enables efficient, scalable, and reproducible modification of cells, supporting the development of cell-based therapies, research, and drug discovery. MaxCyte’s technology is widely used in immuno-oncology, gene editing, and regenerative medicine applications.
Company News
The global transfection technologies market is expected to grow at a CAGR of 9.0% from 2024 to 2032, driven by the rising demand for protein production and advancements in biotechnology.
The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. The company reported fiscal year 2023 losses of 96 cents per share, compared to losses of $3.78 per share from the prior year. Taysha reported it had $143.9 million in cash an...
Penny stocks to watch this week. The post Penny Stocks To Buy This Week? Analysts Like These 3 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The biotech company reduced full-year guidance and expects so-so third-quarter revenue.